About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

USANA Health Sciences, Inc. today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 ...

SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics ...

Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $63.00. Discover ...

The creative services division of Ross Video, Rocket Surgery, and Arcturus have signed an agreement aimed at promoting ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...